Evidence conflicts over efficacy of monoclonal antibodies in severe COVID

Medical team with hospitalized COVID-19 patient
Feb 26, 2021

“We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances.”

Mary Van Beusekom | News Writer | CIDRAP News

Feb 26, 2021
“We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances.”Read More

Leave a Reply

Your email address will not be published.